ArticleFrontiers in endocrinology2026
The association of serum uric acid with severity and prognosis of patients with diabetic foot ulcers.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic foot ulcers (DFU) as one of the most severe complications of diabetes was characterized by high mortality and incidence of cardiovascular events. Serum uric acid (UA) was well known for cause of gout which was closely related with cardiovascular complications, but also known as the main antioxidant in extracellular fluid. In this study, we aimed to investigate whether serum UA was related with severity and prognosis of patients with DFU. Design and methods: 535 patients with diabetes and firstly diagnosed with DFU hospitalized in Ruijin hospital was consecutively recruited. Concentration of serum UA was examined when admission. Participants were grouped into three groups according to tertiles of their serum UA level. These patients were followed up for an average of 48 months to observe the outcomes, including wound healing, non-fatal cerebral and cardiovascular events (NCCE) and all-cause death. The association of serum UA concentration with the severity of disease evaluated through Wagner and Infection degree, and risk of outcomes were analyzed through partial correlation and Cox regression analysis, respectively. Results: In bivariate correlation analysis, UA was negatively correlated with the Wagner (r=-0.159, P <0.001) and Infection degree (r=-0.171, P <0.001). In partial correlation, UA was still negatively and independently correlated with the Wagner (r=-0.74, P <0.001) and Infection degree (r=-0.190, P <0.001) after controlling for age, sex, type of diabetes, duration of diabetes, duration of DFU, PAD, HbA1c, serum creatine and urine protein excretion in 24hours. In terms of Cox regression analysis, UA was positively and independently related with the risk of NCCE (HR = 1.002, 1.000 to 1.004, P = 0.011), all-cause mortality (HR = 1.003, 1.001 to 1.004, P = 0.006) and healing rate (HR = 1.001, 1.000 to 1.003,P = 0.042) after adjusting for age, sex, type of diabetes, duration of diabetes, duration of DFU, history of stroke, history of CAD, PAD, HbA1c, serum creatine and urine protein excretion in 24 hours. Conclusion: UA might exert a beneficial effect in the context of DFU wound repair, but was an important risk factor for NNCE and all-cause mortality in patients with DFU.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.